---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-201376"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:23:11.854547+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics enters $6.15M ATM offering with H.C. Wainwright

## Summary
- Up to $6.15M of common stock may be sold via at-the-market offering with H.C. Wainwright.
- H.C. Wainwright receives 3.0% commission on gross proceeds plus $100K legal reimbursement.
- Net proceeds used for working capital and general corporate purposes.
- Shares will be sold under existing S-3 shelf (Reg. No. 333-284663).
- Company not obligated to sell any shares; no assurance on price or timing.

## SEC filing metadata
- accession: 0001193125-26-201376
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526201376/0001193125-26-201376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526201376/fblg-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-201376
- JSON: https://secwatch.observer/filing/0001193125-26-201376.json
- Plain text: https://secwatch.observer/filing/0001193125-26-201376.txt

## Key facts
- Material Agreements
  FibroBiologics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $6,150,000 (effective 2026-05-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $6,150,000
  - Effective: 2026-05-01
  source text: On May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $6,150,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526201376/0001193125-26-201376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.